 |
Year
2007 |
|
Archives
|
|
|
Researchers debate recreational use of PDE-5 inhibitors
June 21, 2005
Blackwell Publishing --June 21, 2005--Leaders in
the field of sexual medicine will actively debate the use of oral
pills for erectile
dysfunction (ED) at the 7th Congress of the European Society
for Sexual Medicine in London, UK.
Moderated by Irwin Goldstein, MD, editor of the Journal of Sexual
Medicine, the exchange is scheduled to take place on December 5,
2004 in the Palace Suite of the Hilton London Metropole. Journalists
are invited to join a panel posing questions to the use of oral
pills as lifestyle drugs versus medications strictly for health
problems.
Viagra, or sildenafil citrate, the first of the PDE-5 inhibitors
to hit the market in treatment of ED
in 1998, first got its start as a potential angina treatment. Since
then, Vardenafil (Levitra) and
tadalafil (Cialis) have joined the
scene, targeted at millions of men suffering from erectile dysfunction.
Urologists estimate that as many as 152 million men fall into this
group, over half of all men over the age of 40, yet the treatment
for this ailment appeals to numbers beyond. While PDE-5 inhibitors
are technically used to enable men to have an erection when ED is
caused by problems like diabetes, depression, hypertension or prostate
surgery, others see these drugs as an opportunity to enhance their
lifestyle through sexual performance.
Dimitrios Hatzichristou, MD will argue that PDE-5 inhibitors are
excellent lifestyle drugs. With other medications treating hair
loss, obesity, and other conditions not severely life-threatening,
PDE-5 inhibitors have a place in the market for men with and without
erectile dysfunction.
"Erectile dysfunction is an important indicator of serious
underlying medical conditions," writes Geoff Hackett, MD in
a cover story of pH7 Magazine. He will discuss the points behind
taking PDE-5 inhibitors solely as a medication for real health problems.
This event is sponsored by the International Society for Sexual
Medicine and Blackwell Publishing. Journalists wishing to join the
panel for this debate please contact David Ralph, ESSM Program Chair,
at dralph@andrology.co.uk.
About The International Society for Sexual Medicine
The International Society for Sexual Medicine (ISSM) was founded
in 1982 for the purpose of promoting research and exchange of knowledge
for the clinical entity "impotence" throughout the international
scientific community. The principal orientation of ISSM was initially
towards basic science of erection, defects in the erectile mechanism,
and the clinical aspects of diagnosis and treatment of erectile
dysfunction. The focus is now towards the whole field of sexual
medicine. The society has over 2000 members worldwide and there
are five regional societies that are affiliated with ISSM including
the African Society for Sexual and Impotence Research, Asia Pacific
Society for Sexual and Impotence Research, European Society for
Sexual Medicine, Latin American Society for Impotence and Sexuality
Research, and Sexual Medicine Society of North America.
About The Journal of Sexual Medicine
The Journal of Sexual Medicine is the official journal of the International
Society for Sexual Medicine and its five regional affiliate societies.
It is the first journal owned and operated by the societies. The
aim of the journal is to publish multidisciplinary basic science
and clinical research to define and understand the scientific basis
of male and female sexual function and dysfunction. The journal
provides healthcare professionals in sexual medicine with essential
educational content and promotes the exchange of scientific information
generated from experimental and clinical research. The Journal of
Sexual Medicine includes basic science and clinical research studies
in the psychologic and biologic aspects of male and female sexual
function and dysfunction, and highlights new observations and research,
results with innovative treatments and all other topics relevant
to clinical sexual medicine. For more information on The Journal
of Sexual Medicine, please visit http://jsm.issir.org.
About Blackwell Publishing
Blackwell Publishing is the world's leading society publisher, partnering
with more than 550 academic and professional societies. Blackwell
publishes over 750 journals and 600 text and reference books annually,
across a wide range of academic, medical, and professional subjects.
The company remains independent with over 900 staff members in offices
in the US, UK, Australia, China, Denmark, Germany, and Japan. Blackwell's
mission as an expert publisher is to create long-term partnerships
with our clients that enhance learning, disseminate research, and
improve the quality of professional practice. For more information
on Blackwell Publishing, please visit http:// www.blackwellpublishing.com
or http:// www.blackwell-synergy.com.
Contact: Sharon Agsalda
medicalnews@bos.blackwellpublishing.com
781-388-8507
Blackwell Publishing Ltd
Source: http://archives.moneyplans.net
| 
